Barzolvolimab Shows Promise in CSU
Chronic spontaneous urticaria (CSU) is getting a lot of attention these days as researchers close in on the role mast cells play in causing hives. Top-line results from a phase 2 trial show that barzolvolimab (anti-KIT monoclonal antibody) improves symptoms in patients with antihistamine-refractory CSU. “Barzolvolimab successfully decreased disease activity in patients with moderate to […]
For the Win: Cerave Scores Big with SuperBowl Ad
For weeks, actor Michael Cera has been in the news and across social media promoting his ‘namesake’ brand, CeraVe. In the new ad, Cera goes toe-to-toe with dermatologists and reveals his very own Michael CeraVe commercial, but Cera’s bizarre campaign gets debunked by a boardroom of CeraVe dermatologists, who reminded him that CeraVe is and always has […]
On the Horizon: New, Non-invasive Light-based Techniques May Help Detect Skin Cancer in Older Adults
When examined under polarized laser light, ageing skin looks noticeably different than younger skin, and this finding could pave the way for new, non-invasive light-based techniques to detect skin cancer in older individuals. The new study indicates that the altered light scattering properties of ageing skin are largely due to changes in the skin’s texture, […]
Get to Know Alys Pharmaceuticals, Inc.
Alys Pharmaceuticals, Inc. is coming out of the gate strong with $100M financing from Medicxi to advance its immuno-dermatology focused pipeline. Alys combines six asset-centric Medicxi companies including Al Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. Co-founded by Medicxi and several dermatology and scientific experts, including TDD Editorial Advisory Board member John […]